The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels
E Iivanainen, S Lauttia, N Zhang, D Tvorogov… - Microvascular …, 2009 - Elsevier
Drugs that target EGFR have established anti-tumor effect and are used in the clinic. Here
we addressed whether inhibition of EGFR tyrosine kinase activity by gefitinib in tumor
microenvironment affected tumor angiogenesis or vasculogenesis. A syngeneic tumor
model of mice with grafted GFP-labeled bone marrow cells was used to analyze the effects
of gefitinib on different cellular components of tumor vasculature. To characterize tumor cell-
independent stromal effects of EGFR targeting, the mice were injected with B16 melanoma …
we addressed whether inhibition of EGFR tyrosine kinase activity by gefitinib in tumor
microenvironment affected tumor angiogenesis or vasculogenesis. A syngeneic tumor
model of mice with grafted GFP-labeled bone marrow cells was used to analyze the effects
of gefitinib on different cellular components of tumor vasculature. To characterize tumor cell-
independent stromal effects of EGFR targeting, the mice were injected with B16 melanoma …